Darovasertib/Crizotinib Shows Early Efficacy in Metastatic Uveal Melanoma

Source: Targeted Oncology, December 2021

Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.

Preliminary results from a trial of darovasertib (IDE196) and crizotinib (Xalkori) demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma (MUM), according to a press release from IDEAYA Biosciences.1

The multi-arm phase 1/2 trial (NCT03947385) of darovasertib in solid tumors is exploring the use of darovasertib as a monotherapy, as a combination with crizotinib, and as a combination with binimetinib (Mektovi). Previous results of the binimetinib combination arm demonstrated a favorable overall survival (OS) and overall response rate (ORR) compared with historically low ORRs for other MUM treatments.